NCT07026994View on ClinicalTrials.gov

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar
Interventions
DRUG

Colchicine 0.5mg

Oral colchicine 0.5mg once per day combined with standard treatment

DRUG

Matching placebo

Oral matching placebo once per day combined with standard treatment

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

RECRUITING

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

collaborator

West China Hospital

OTHER

lead

Huashan Hospital

OTHER

NCT07026994 - Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage | Biotech Hunter | Biotech Hunter